BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.
作者信息
Mao Chen, Liao Ru-Yan, Chen Qing
出版信息
J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. doi: 10.1007/s00432-010-0922-8. Epub 2010 Jun 1.
Abstract
摘要
相似文献
1
BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.
J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. doi: 10.1007/s00432-010-0922-8. Epub 2010 Jun 1.
2
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
Mol Biol Rep. 2011 Apr;38(4):2219-23. doi: 10.1007/s11033-010-0351-4. Epub 2010 Sep 21.
3
Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Mol Biol Rep. 2014 Mar;41(3):1291-8. doi: 10.1007/s11033-013-2974-8. Epub 2014 Jan 4.
4
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13.
5
Treatment of extended RAS/ wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.
Pharmacogenomics. 2025 Jan-Feb;26(1-2):39-52. doi: 10.1080/14622416.2025.2479414. Epub 2025 Mar 17.
6
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19.
7
BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis.
Chin Med Sci J. 2014 Dec;29(4):197-203. doi: 10.1016/s1001-9294(14)60070-5.
8
Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
Mol Med. 2013 Feb 8;18(1):1519-26. doi: 10.2119/molmed.2012.00175.
9
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.
10
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29.
引用本文的文献
1
SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment.
Exploration (Beijing). 2022 May 9;2(3):20210176. doi: 10.1002/EXP.20210176. eCollection 2022 Jun.
2
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
J Korean Med Sci. 2017 Jan;32(1):38-46. doi: 10.3346/jkms.2017.32.1.38.
3
Mutations of the functional ARH1 allele in tumors from ARH1 heterozygous mice and cells affect ARH1 catalytic activity, cell proliferation and tumorigenesis.
Oncogenesis. 2015 Jun 1;4(6):e151. doi: 10.1038/oncsis.2015.5.
本文引用的文献
1
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.
2
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.
3
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.
4
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
Zotero 插件